Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

Cancer

Volumn 118, Issue 22, 2012, Pages 5709-5718

  Nelson, Joel B ^a   Fizazi, Karim ^b   Miller, Kurt ^c   Higano, Celestia ^d   Moul, Judd W ^e   Akaza, Hideyuki ^f   Morris, Thomas ^g   McIntosh, Stuart ^g   Pemberton, Kristine ^g   Gleave, Martin ^h  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF WASHINGTON   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF TOKYO   (Japan)

^g ASTRAZENECA   (United Kingdom)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

castration resistant prostate cancer; endothelin; ET 1; phase 3; zibotentan

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; ZIBOTENTAN;

ADULT; AGE; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BONE METASTASIS; CANCER PAIN; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CEREBROVASCULAR ACCIDENT; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; GEOGRAPHY; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; OVERALL SURVIVAL; PALLIATIVE THERAPY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; URINE RETENTION; VOMITING;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DISEASE-FREE SURVIVAL; ENDOTHELIN-1; HUMANS; MALE; ORCHIECTOMY; PLACEBOS; PROSTATIC NEOPLASMS; PYRROLIDINES; RECEPTOR, ENDOTHELIN A; SURVIVAL; TREATMENT OUTCOME;

EID: 84868200731     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27674     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Kasper S, Cookson MS,. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am. 2006; 33: 201-210.
3. Nelson J, Bagnato A, Battistini B, Nisen P,. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003; 3: 110-116.
4. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996; 56: 663-668.
5. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003; 100: 10954-10959.
6. Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med. 1998; 4: 50-57.
7. Nelson JB, Udan MS, Guruli G, Pflug BR,. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia. 2005; 7: 631-637.
8. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, Phase II trial. Eur Urol. 2009; 55: 1112-1123.
9. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int. 2010; 106: 966-973.
10. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.
11. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411-422.
12. Basch EM, Somerfield MR, Beer TM, et al. American Society of Clinical Oncology. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol. 2007; 25: 5313-5318.
13. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010; 376: 1147-1154.
14. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
15. Medivation and Astellas announce positive survival data from interim analysis of Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer [press release]. November 3, 2011; San Francisco, CA: Medivation, Inc. http://investors.medivation.com/releasedetail.cfm?ReleaseID=620500.
16. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a Phase III randomized trial (ALSYMPCA). Eur J Cancer. 2011; 47 (suppl 2): 3. Abstract 1LBA.
17. Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK,. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004. Cancer. 2007; 110: 1255-1263.
18. Fujimoto H, Nakanishi H, Miki T, et al. Oncological outcomes of the prostate cancer patients registered in 2004: Report from the Cancer Registration Committee of the JUA. Int J Urol. 2011; 18: 876-881.
19. Scher HI, Morris MJ, Basch E, Heller G,. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011; 29: 3695-3704.
20. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003; 21: 679-689.
21. Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol. 2003; 169: 1143-1149.
22. Armstrong AJ, Creel P, Turnbull J, et al. A Phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2008; 14: 6270-6276.
23. Bishr M, Lattouf JB, Gannon PO, Saad F,. Updates on therapeutic targets and agents in castration-resistant prostate cancer. Minerva Urol Nefrol. 2011; 63: 131-143.
24. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007; 110: 1959-1966.
25. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer. 2008; 113: 2478-2487.
26. Scher HI, Halabi S, Tannock I, et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.
27. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D,. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007; 17: 584-590.
28. George D, Moul JW,. Emerging treatment options for patients with castration-resistant prostate cancer. Prostate. 2012; 72: 338-349.
29. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377: 813-822.
30. US National Institutes of Health, ClinicalTrials.gov. A study evaluating the clinical benefit of adding custirsen to docetaxel retreatment/prednisone as second line therapy in men with castrate resistant prostate cancer (CRPC). 2011. http://clinicaltrials.gov/ct2/show/NCT01083615?term=OGX-011&rank=9.
31. US National Institutes of Health, ClinicalTrials.gov. Study comparing orteronel plus prednisone in patients with metastatic castration-resistant prostate cancer. 2011. http://clinicaltrials.gov/ct2/show/NCT01193257?term= orteronel%2C+prostate+cancer%2C+Phase +III&rank=2.
32. US National Institutes of Health, ClinicalTrials.gov. Study comparing orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. 2011. http://clinicaltrials.gov/ct2/show/ NCT01193244?term=orteronel%2C+prostate+ cancer%2C+Phase+III&rank=1.
33. US National Institutes of Health, ClinicalTrials.gov. A study of tasquinimod in men with metastatic castrate resistant prostate cancer. 2011. http://clinicaltrials.gov/ct2/show/NCT01234311?term=tasqui nimod%2C+prostate+cancer%2C+Phase+III&rank=1.
34. US National Institutes of Health, ClinicalTrials.gov. A safety and efficacy study of oral MDV3100 in chemotherapy-naive patients with progressive metastatic prostate cancer (PREVAIL). 2012. http://clinicaltrials.gov/ct2/show/ NCT01212991?term=MDV3100& rank=7.
35. Chi KN, Hotte SJ, Yu EY, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28: 4247-4254.